Form 4: Gilead Sciences SVP, Controllership, Sandra Patterson, Reports Changes in Beneficial Ownership

Sandra Patterson, SVP, Controllership at Gilead Sciences, reports transactions involving common stock and restricted stock units.

Summary

• On March 10, 2024, Sandra Patterson, SVP, Controllership at Gilead Sciences, engaged in transactions involving the company's common stock and derivative securities.
• These transactions included the vesting of restricted stock units (RSUs) and the acquisition of shares through the Employee Stock Purchase Plan.
• Patterson acquired 748 shares and 1,934 shares of common stock through RSU vesting.
• She also disposed of 790 shares to cover tax obligations at a price of $75.12.
• Additionally, Patterson acquired 13,660 non-qualified stock options and 4,825 restricted stock units.
• Following these transactions, Patterson directly owns 32,632 shares of Gilead Sciences common stock, 13,838 and 18,663 restricted stock units, and 13,660 non-qualified stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to stock-based compensation and does not indicate any significant positive or negative developments.

Positives

• The acquisition of shares through RSU vesting and the Employee Stock Purchase Plan indicates Patterson's continued investment in Gilead Sciences.
• The grant of stock options aligns Patterson's interests with those of the shareholders, incentivizing her to drive company performance.

Negatives

• The disposal of 790 shares to cover tax obligations, while routine, represents a slight reduction in Patterson's direct holdings.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's confidence in the company's prospects.

Comparison to Industry Standards

• Tracking insider transactions is a common practice in financial analysis.
• Comparing Patterson's transactions to those of other executives at Gilead and peer companies can provide insights into relative valuation and sentiment.
• Companies like Amgen, AbbVie, and Johnson & Johnson are often used as benchmarks for Gilead in terms of executive compensation and stock ownership.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• However, transparency in insider transactions is important for maintaining investor confidence.

Key Dates